FDA approved Augmentin XR (amoxicillin-clavulanate potassium) under the Commissioner’s National Priority Voucher pilot program, marking the first approval achieved through this review pathway.
In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA.
